Visceral leishmaniasis in renal transplant recipients: successful treatment with liposomal amphotericin B (AmBisome).
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 10451172.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Visceral leishmaniasis (VL) is a rare disease in renal transplant recipients. Liposomal amphotericin B (AmBisome) is known to be effective against VL. However, previously there has been no experience with administration of such treatment to renal transplant recipients. We report herein four patients with VL complicating renal transplantation who were treated successfully with liposomal amphotericin B (total dose, 23-40 mg/kg). Neither adverse reactions nor clinical relapses of VL were observed.
Medical subject headings
- Amphotericin B
- Antiprotozoal Agents
- Kidney Transplantation
- Leishmaniasis, Visceral